This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Partners HealthCare Extends Agreement With Omnicell For Medication Automation

MOUNTAIN VIEW, Calif., Oct. 23, 2012 /PRNewswire/ -- Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication and supply management solutions and analytics software for healthcare facilities, today announced the renewal of its contract with the top-ranked non-profit, integrated health system Partners HealthCare. Following more than a decade of success using Omnicell solutions throughout its hospitals, Partners HealthCare chose to extend its relationship with Omnicell with an exclusive agreement for pharmacy automation.

(Logo: http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a)

Partners HealthCare was founded by two of the nation's leading academic medical centers, Brigham and Women's Hospital and Massachusetts General Hospital. Those hospitals consistently rank among the top ten hospitals nationwide in the U.S. News & World Report Best Hospitals. Massachusetts General Hospital was ranked first and Brigham and Women's Hospital was ranked ninth in the report's 2012-2013 national Honor Roll.

Partners HealthCare's decision to continue its relationship with Omnicell is the most recent example of the health system's ongoing efforts to provide the most innovative clinician-centered technology.

"We have built our reputation as a world-class institution by giving the best care to our patients. Ensuring that we have the leading technology on the market is vital to the safety of our patients and our hospitals' continued success," said William Churchill, M.S., R.Ph., executive director of pharmacy services, Brigham and Women's Hospital.

This exclusive agreement reflects Partners HealthCare's commitment to providing the highest quality of care while ensuring both patient and clinician satisfaction. To date, Omnicell's medication automation solutions are implemented throughout the hospitals within the Partners HealthCare system, including pharmacy, nursing and anesthesia workstations in operating rooms, with plans for increased deployment over the course of this contract.

"Technology-based solutions have helped tremendously in managing workflow and standardizing operations within Partners HealthCare," said Meg Clapp, chief pharmacy officer, Massachusetts General Hospital. "Advances like automated dispensing cabinets, medication carts, pharmacy carousels and medication packaging software allow our clinicians to more readily access the medication, supplies and information they need to provide our patients with the exceptional care they have come to expect from our facilities."

"Omnicell shares in Partners HealthCare's commitment to the highest standards of patient safety, clinician satisfaction and overall care quality," said J. Christopher Drew, executive vice president, field operations at Omnicell. "We are pleased to continue our relationship with Partners HealthCare to provide Omnicell's leading medication automation solutions throughout its hospitals to help fulfill its goal of offering patient-specific solutions. We look forward to working with Partners HealthCare as it succeeds in its mission to provide outstanding care to the greater Boston community."



1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,000.02 +17.43 0.10%
S&P 500 1,980.40 +1.49 0.08%
NASDAQ 4,460.7410 +15.8320 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs